150 related articles for article (PubMed ID: 31838901)
1. Discovering novel P38α inhibitors for the treatment of prostate cancer through virtual screening methods.
Li K; Li Z; Tao Y; Wang Q; Lai Y; Wu W; Peng S; Guo Z; Huang H
Future Med Chem; 2019 Dec; 11(24):3125-3137. PubMed ID: 31838901
[No Abstract] [Full Text] [Related]
2. Design and molecular modeling of novel P38α MAPK inhibitors targeting breast cancer, synthesized from oxygen heterocyclic natural compounds.
Abdelhafez OM; Ahmed EY; Abdel Latif NA; Arafa RK; Abd Elmageed ZY; Ali HI
Bioorg Med Chem; 2019 Apr; 27(7):1308-1319. PubMed ID: 30792101
[TBL] [Abstract][Full Text] [Related]
3. Development of peptide inhibitor as a therapeutic agent against head and neck squamous cell carcinoma (HNSCC) targeting p38alpha MAP kinase.
Gill K; Singh AK; Kapoor V; Nigam L; Kumar R; Holla P; Das SN; Yadav S; Subbarao N; Mohanti BK; Dey S
Biochim Biophys Acta; 2013 Mar; 1830(3):2763-9. PubMed ID: 23238519
[TBL] [Abstract][Full Text] [Related]
4. Discovery of potent p38α MAPK inhibitors through a funnel like workflow combining in silico screening and in vitro validation.
Astolfi A; Kudolo M; Brea J; Manni G; Manfroni G; Palazzotti D; Sabatini S; Cecchetti F; Felicetti T; Cannalire R; Massari S; Tabarrini O; Loza MI; Fallarino F; Cecchetti V; Laufer SA; Barreca ML
Eur J Med Chem; 2019 Nov; 182():111624. PubMed ID: 31445234
[TBL] [Abstract][Full Text] [Related]
5. Tetra-substituted pyridinylimidazoles as dual inhibitors of p38α mitogen-activated protein kinase and c-Jun N-terminal kinase 3 for potential treatment of neurodegenerative diseases.
Muth F; Günther M; Bauer SM; Döring E; Fischer S; Maier J; Drückes P; Köppler J; Trappe J; Rothbauer U; Koch P; Laufer SA
J Med Chem; 2015 Jan; 58(1):443-56. PubMed ID: 25475894
[TBL] [Abstract][Full Text] [Related]
6. Pharmacophore-based virtual screening, molecular docking, molecular dynamics simulation, and biological evaluation for the discovery of novel BRD4 inhibitors.
Yan G; Hou M; Luo J; Pu C; Hou X; Lan S; Li R
Chem Biol Drug Des; 2018 Feb; 91(2):478-490. PubMed ID: 28901664
[TBL] [Abstract][Full Text] [Related]
7. Synthesis and pharmacological screening of a large library of 1,3,4-thiadiazolines as innovative therapeutic tools for the treatment of prostate cancer and melanoma.
De Monte C; Carradori S; Secci D; D'Ascenzio M; Guglielmi P; Mollica A; Morrone S; Scarpa S; Aglianò AM; Giantulli S; Silvestri I
Eur J Med Chem; 2015 Nov; 105():245-62. PubMed ID: 26498571
[TBL] [Abstract][Full Text] [Related]
8. Discovering new mTOR inhibitors for cancer treatment through virtual screening methods and in vitro assays.
Wang L; Chen L; Yu M; Xu LH; Cheng B; Lin YS; Gu Q; He XH; Xu J
Sci Rep; 2016 Jan; 6():18987. PubMed ID: 26732172
[TBL] [Abstract][Full Text] [Related]
9. Synthesis and molecular docking study of new benzofuran and furo[3,2-g]chromone-based cytotoxic agents against breast cancer and p38α MAP kinase inhibitors.
Amin KM; Syam YM; Anwar MM; Ali HI; Abdel-Ghani TM; Serry AM
Bioorg Chem; 2018 Feb; 76():487-500. PubMed ID: 29310080
[TBL] [Abstract][Full Text] [Related]
10. p38α MAPK and Type I Inhibitors: Binding Site Analysis and Use of Target Ensembles in Virtual Screening.
Astolfi A; Iraci N; Sabatini S; Barreca ML; Cecchetti V
Molecules; 2015 Aug; 20(9):15842-61. PubMed ID: 26334265
[TBL] [Abstract][Full Text] [Related]
11. Fragment-Based Structural Optimization of a Natural Product Itampolin A as a p38α Inhibitor for Lung Cancer.
Liang JW; Wang MY; Wang S; Li XY; Meng FH
Mar Drugs; 2019 Jan; 17(1):. PubMed ID: 30642059
[TBL] [Abstract][Full Text] [Related]
12. Discovery of novel human inosine 5'-monophosphate dehydrogenase 2 (hIMPDH2) inhibitors as potential anticancer agents.
Shah CP; Kharkar PS
Eur J Med Chem; 2018 Oct; 158():286-301. PubMed ID: 30223117
[TBL] [Abstract][Full Text] [Related]
13. Lysophosphatidic acid induces prostate cancer PC3 cell migration via activation of LPA(1), p42 and p38alpha.
Hao F; Tan M; Xu X; Han J; Miller DD; Tigyi G; Cui MZ
Biochim Biophys Acta; 2007 Jul; 1771(7):883-92. PubMed ID: 17531530
[TBL] [Abstract][Full Text] [Related]
14. Computer-aided drug discovery of Myc-Max inhibitors as potential therapeutics for prostate cancer.
Carabet LA; Lallous N; Leblanc E; Ban F; Morin H; Lawn S; Ghaidi F; Lee J; Mills IG; Gleave ME; Rennie PS; Cherkasov A
Eur J Med Chem; 2018 Dec; 160():108-119. PubMed ID: 30326371
[TBL] [Abstract][Full Text] [Related]
15. Design, Synthesis, and Molecular Docking of Novel Miscellaneous Chalcones as p38α Mitogen-Activated Protein Kinase Inhibitors.
Zeid MM; El-Badry OM; Elmeligie S; Hassan RA
Chem Biodivers; 2024 Apr; 21(4):e202400077. PubMed ID: 38359316
[TBL] [Abstract][Full Text] [Related]
16. Machine Learning Assisted Discovery of Novel p38α Inhibitors from Natural Products.
Shen T; Tao Y; Liu B; Kong D; Zhang R; Xiao W
Comb Chem High Throughput Screen; 2023; 26(6):1214-1223. PubMed ID: 35786181
[TBL] [Abstract][Full Text] [Related]
17. Discovery of small molecules targeting GRP78 for antiangiogenic and anticancer therapy.
Qiao Y; Dsouza C; Matthews AA; Jin Y; He W; Bao J; Jiang F; Chandna R; Ge R; Fu L
Eur J Med Chem; 2020 May; 193():112228. PubMed ID: 32199134
[TBL] [Abstract][Full Text] [Related]
18. Recent developments of p38α MAP kinase inhibitors as antiinflammatory agents based on the imidazole scaffolds.
Kong TT; Zhang CM; Liu ZP
Curr Med Chem; 2013; 20(15):1997-2016. PubMed ID: 23317165
[TBL] [Abstract][Full Text] [Related]
19. Discovery of novel pyruvate dehydrogenase kinases inhibitors by screening of an in-house small molecule library for anti-lung cancer therapeutics.
Guo F; Zhao S; Li X
Bioorg Med Chem Lett; 2019 Jan; 29(2):291-296. PubMed ID: 30470491
[TBL] [Abstract][Full Text] [Related]
20. Discovery of the first chemical tools to regulate MKK3-mediated MYC activation in cancer.
Yang X; Fan D; Troha AH; Ahn HM; Qian K; Liang B; Du Y; Fu H; Ivanov AA
Bioorg Med Chem; 2021 Sep; 45():116324. PubMed ID: 34333394
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
